Talaris raises $100M series A, reports 70% immune tolerance for allogeneic cell therapy

With a new management team at the helm, Talaris raised $100 million in a series A round Thursday and reported that FCR001 led to a 70% immune tolerance rate in a Phase II trial to induce durable immune tolerance in living donor kidney transplant recipients. The company, formerly Regenerex LLC, plans to start a Phase III trial this year of the allogeneic cell therapy.

The financing, which will provide the company with 3.5 years of runway, was led by Blackstone Life Sciences, with participation from Longitude Capital and Qiming Venture Partners USA...